Recombinant Human IFN-α1b #abs00912

abs00912-2ug

1-2 Weeks

138

abs00912-10ug

1-2 Weeks

344

abs00912-1mg

1-2 Weeks

1945

Species

Human

Source

Escherichia coli.

Format

The solution in PBS, pH 7.4, containing 4% mannitol and 1% HSA was filtered through a 0.2 μm sieve and then lyophilized. It was carefully processed to form a dry product while preserving its original composition. The inclusion of mannitol and HSA ensures stability and compatibility with the intended application. The resulting lyophilized material can be easily reconstituted, making it convenient for use in various research and medical settings.

Properties

aa_sequence

LMQDSSCAWDE LMDRHDFGFP QMSRISPSSC KAPAISVLHE LIQQIFNLFT DLLDKFCTEL YQQLNDLEAC MCDLPETHSL DNRRTLMLLA QEEFDGNQFQ VMQEERVGET PLMNVDSILA VKKYFRRITL YLTEKKYSPC AWEVVRAEIM RSLSLSTNLQ ERLRRKE
This text is similar to the original content but has been rearranged for readability. The words and letters used are the same as in the original text, but the order has been changed to create a new version of the same information.

Concentration

> 96 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The LAL method determined that the Recombinant Human IFN-α1b contained less than 1 EU/μg. It is important to note that this information is derived from the original text.

Activity

This product is just as biologically active as the standard, and has been confirmed by an anti-viral assay to have a specific activity level of at least 1.0 × 10. This ensures that the product maintains the same potency and effectiveness as the standard, making it a reliable choice for a variety of uses.⁸ IU/mg.

Reconstitution

It is recommended to briefly centrifuge this vial prior to opening in order to ensure that the contents settle at the bottom. To reconstitute, use sterile distilled water or an aqueous buffer that contains 0.1 % BSA to achieve a concentration of 0.1-1.0 mg/mL. Stock solutions should be divided into working aliquots and stored at temperatures of -20 °C or below. Any further dilutions should be made using appropriate buffered solutions for optimal results.

Stability & Storage

The lyophilized preparation can be stored at 2-8 °C, but it is recommended to keep it at -20 °C for long-term storage, with desiccation preferred. Once reconstituted, the preparation remains stable for up to a week if stored at 2-8 °C. For optimum stability, divide the reconstituted preparation into small aliquots and store them at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles to prevent deterioration of the preparation. To generate new content based on this information, one could rephrase it as follows: To preserve the integrity of this lyophilized preparation, it is advisable to keep it at -20 °C, with desiccation being the preferred method of storage. Although it is stable at 2-8 °C for short periods, it should be stored in smaller working aliquots that can be frozen at -20 °C to -70 °C. Any freeze/thaw cycles could lead to degradation of the reconstituted preparation and should be avoided.

Target

Accession

P01562

Gene IDs

3439

References

References

1. Tarhini AA, Gogas H, Kirkwood JM. 2012. J Immunol, 189: 3789-93.

2. Tohyama M, Yang L, Hanakawa Y, et al. 2012. J Invest Dermatol, 132: 1933-5.

3. Corssmit EP, Heijligenberg R, Hack CE, et al. 1997. Clin Exp Immunol, 107: 359-63.

4. Corssmit EP, de Metz J, Sauerwein HP, et al. 2000. J Interferon Cytokine Res, 20: 1039-47.